Molecular imaging of HPMA copolymers: Visualizing drug delivery in cell, mouse and man

Advanced Drug Delivery Reviews

Volumn 62, Issue 2, 2010, Pages 246-257

  Lu, Zheng Rong ^a  

^a Case Western Reserve University   (United States)

Author keywords

Drug delivery; Fluorescence imaging; HPMA copolymers; Molecular imaging; MRI; PET; Polymer drug conjugates; SPECT

Indexed keywords

FLUORESCENCE IMAGING; HPMA COPOLYMERS; MOLECULAR IMAGING; MRI; PET POLYMER;

COMPUTER CRIME; COPOLYMERIZATION; COPOLYMERS; DRUG DELIVERY; FLUORESCENCE; MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POLYETHYLENE TEREPHTHALATES; RESONANCE;

PLASTIC PRODUCTS;

DOXORUBICIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GEMCITABINE; INDIUM 111; IODINE 131; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYGLUTAMIC ACID; TECHNETIUM 99M; ACRYLAMIDE DERIVATIVE; N-(2-HYDROXYPROPYL)METHACRYLAMIDE; POLYMER;

AQUEOUS SOLUTION; BREAST CANCER; CELL COMPARTMENTALIZATION; CELL SURFACE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; CONTRAST ENHANCEMENT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOCYTOSIS; FLUORESCENCE IMAGING; GAMMA SCINTIGRAPHY; HUMAN; INTERNALIZATION; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; POLYMERIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CELL LINE; CELL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; MOUSE; PROCEDURES;

ACRYLAMIDES; ANIMALS; CELL LINE; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MOLECULAR IMAGING; POLYMERS;

EID: 75749117588     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.12.007     Document Type: Review

References (40)

1. Kopeèek J. Soluble biomedical polymers. Polim. Med. 7 (1977) 191-221
2. Kopeček J. Controlled biodegradability of polymers-a key to drug delivery systems. Biomaterials 5 (1984) 19-25
3. Kopeček J., Kopecková P., Minko T., and Lu Z.-R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50 (2000) 61-81
4. Lu Z.-R., Shiah J.G., Sakuma S., Kopecková P., and Kopeček J. Design of novel bioconjugates for targeted drug delivery. J. Control. Release 78 (2002) 165-173
5. Thomson A.H., Vasey P.A., Murray L.S., Cassidy J., Fraier D., Frigerio E., and Twelves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 81 (1999) 99-107
6. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J., and Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668
7. Gianasi E., Wasil M., Evagorou E.G., Keddle A., Wilson G., and Duncan R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumor activity in vivo. Eur. J. Cancer. 35 (1999) 994
8. Borgman M.P., Coleman T., Kolhatkar R.B., Geyser-Stoops S., Line B.R., and Ghandehari H. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A″-DTPA) conjugates show increased kidney accumulation. J. Control. Release. 132 (2008) 193-199
9. Lu Z.-R., Kopecková P., and Kopeček J. Polymerizable Fab′, antibody fragments for targeting of anticancer drugs. Nat. Biotechnol. 17 (1999) 1101-1104
10. Wang D., Miller S.C., Sima M., Parker D., Buswell H., Goodrich K.C., Kopecková P., and Kopeček J. The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm. Res. 21 (2004) 1741-1749
11. York A.W., Scales C.W., Huang F., and McCormick C.L. Facile synthetic procedure for omega, primary amine functionalization directly in water for subsequent fluorescent labeling and potential bioconjugation of RAFT-synthesized (co)polymers. Biomacromolecules 8 (2007) 2337-2341
12. Jensen K.D., Kopecková P., Bridge J.H., and Kopeček J. The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci. 3 (2001) E32
13. Lammers T., Subr V., Ulbrich K., Peschke P., Huber P.E., Hennink W.E., and Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30 (2009) 3466-3475
14. Lu Z.-R., Shiah J.-G., Kopeckova P., and Kopeček J. Polymerizable Fab′ antibody fragments targeted photodynamic cancer therapy in nude mice. STP Pharm. Sci. 13 (2003) 69-75
15. Omelyanenko V., Gentry C., Kopecková P., and Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75 (1998) 600-608
16. Omelyanenko V., Kopecková P., Gentry C., and Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 53 (1998) 25-37
17. Nori A., Jensen K.D., Tijerina M., Kopecková P., and Kopeček J. Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. J. Control. Release 91 (2003) 53-59
18. Cuchelkar V., Kopecková P., and Kopeček J. Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol Pharm. 5 (2008) 776-786
19. Seib F.P., Jones A.T., and Duncan R. Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer-doxorubicin. J. Drug Target 14 (2006) 375-390
20. Z.-R. Lu. In vivo imaging of dosage forms. Modern Pharmaceutics, 5th, Vol 1. A.T. Florence and J Siepmann Ed. Pp 181-201.
21. Wang Y., Ye F., Jeong E.K., Sun Y., Parker D.L., and Noninvasive Z.R.Lu. visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI. Pharm. Res. 24 (2007) 1208-1216
22. Lu Z.-R., Ye F., and Vaidya A. Polymer platforms for drug delivery and biomedical imaging. J. Control. Release 122 (2007) 269-277
23. Kiessling F., Heilmann M., Lammers T., Ulbrich K., Subr V., Peschke P., Waengler B., Mier W., Schrenk H.H., Bock M., Schad L., and Semmler W. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. Bioconjug. Chem. 17 (2006) 42-51
24. Pimm M.V., Perkins A.C., Duncan R., and Ulbrich K. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Target. 1 2 (1993) 125-131
25. Pimm M.V., Perkins A.C., Strohalm J., Ulbrich K., and Duncan R. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J. Drug Target. 3 (1996) 375-383
26. Pimm M.V., Perkins A.C., Strohalm J., Ulbrich K., and Duncan R. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J. Drug Target. 3 (1996) 385-390
27. Lammers T., Kühnlein R., Kissel M., Subr V., Etrych T., Pola R., Pechar M., Ulbrich K., Storm G., Huber P., and Peschke P. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J. Control Release 110 (2005) 103-118
28. Mitra A., Nan A., Ghandehari H., McNeill E., Mulholland J., and Line B.R. Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution. Pharm Res. 21 (2004) 1153-1159
29. Lammers T., Peschke P., Kühnlein R., Subr V., Ulbrich K., Debus J., Huber P., Hennink W., and Storm G. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control Release 117 (2007) 333-341
30. Kissel M., Peschke P., Subr V., Ulbrich K., Strunz A.M., Kühnlein R., Debus J., and Friedrich E. Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1055-1062
31. Herth M.M., Barz M., Moderegger D., Allmeroth M., Jahn M., Thews O., Zentel R., and Rösch F. Radioactive labeling of defined HPMA-based polymeric structures using [(18)F]FETos for in vivo imaging by positron emission tomography. Biomacromolecules 10 (2009) 1687-1703
32. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J., and Cancer Research Campaign Phase I/II Committee. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
33. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., and Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 34 (2009) 1629-1636
34. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin C.M., Doran J., David M., Anderson D., Christodoulou C., Young A.M., Hesslewood S., and Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control Release 57 (1999) 281-290
35. Gainkam L.O., Huang L., Caveliers V., Keyaerts M., Hernot S., Vaneycken I., Vanhove C., Revets H., De Baetselier P., and Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med. 49 (2008) 788-795
36. Beauregard J.M., Croteau E., Ahmed N., van Lier J.F., and Bénard F. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT. J. Nucl. Med. 50 (2009) 100-107
37. Wehrl H.F., Judenhofer M.S., Wiehr S., and Pichler B.J. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur. J. Nucl. Med. Mol. Imaging 36 Suppl 1 (2009) S56-S68
38. Vaidya A., Sun Y., Ke T., Jeong E.K., and Lu Z.R. Contrast enhanced MRI-guided photodynamic therapy for site-specific cancer treatment. Magn. Reson. Med. 56 (2006) 761-767
39. Vaidya A., Sun Y., Feng Y., Emerson L., Jeong E.K., and Lu Z.R. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm. Res. 25 (2008) 2002-2011
40. Lammers T., Subr V., Peschke P., Kühnlein R., Hennink W.E., Ulbrich K., Kiessling F., Heilmann M., Debus J., Huber P.E., and Storm G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer. 99 (2008) 900-910